Skip to main content
Premium Trial:

Request an Annual Quote

Whitehead picks protein fan for Director

Premium

With the drama of the human genome project behind it, the next main event for the Whitehead Institute for Biomedical Research at MIT remains a question. Its new director has her work cut out for her.

Susan Lindquist, who replaces Gerald Fink, says she hopes to build on Whitehead’s well-known strengths by continuing to integrate its sequencing expertise with other areas of biological research. “One of the major goals of our development campaign is going to be the next generation of proteomics and genomics beyond just sequencing,” she says.

The choice of Lindquist, who has studied the cellular mechanisms that govern protein conformation, seems to indicate a step more in the direction of protein research. But she downplays the significance of her research background in her appointment, saying that the institute is already quite diverse in the scope of its research. “I’m not going to make any major changes,” the University of Chicago protein chemist says. Also, she adds, at least half of the members of the institute “are at one level or another doing things that involve chips or proteomics, or soon will be.”

Lindquist’s watchword could be collaboration — among researchers and between public and private entities. “Everybody sees the key to the future — for not just the Whitehead but biology in general — is pushing new frontiers and new collaborative interactions between people who didn’t necessarily collaborate before, such as between physicists, engineers, and biologists,” she says.

In addition, she hopes the institute will play a greater role as a partner to industry and philanthropic foundations to find ways to quickly apply basic research to solve problems, particularly in medicine. “It’s vital for the health of research that a lot of it be publicly funded, that I will say straight up from the very beginning,” Lindquist says. “But I also feel it’s important that the research winds up being translated into doing good in people’s lives as quickly as possible, and that means collaborating with industry and also with foundations and philanthropic individuals.”

— John S. MacNeil

 

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.